emedastine has been researched along with Conjunctivitis, Allergic in 13 studies
emedastine: structure given in first source
emedastine : 1-Methyl-1,4-diazepane in which the hydrogen attached to the nitrogen at position 4 is substituted by a 1-(2-ethoxyethyl)-1H-benzimidazol-2-yl group. A relatively selective histamine H1 antagonist, it is used as the difumatate salt for allergic rhinitis, urticaria, and pruritic skin disorders, and in eyedrops for the symptomatic relief of allergic conjuntivitis.
Conjunctivitis, Allergic: Conjunctivitis due to hypersensitivity to various allergens.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)." | 9.14 | Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. ( Akman, A; Akova, YA; Borazan, M; Erbek, SS; Karalezli, A; Kiyici, H, 2009) |
| " The aims of the present study were to establish whether there is a rapid effect of eyedrops containing the selective H1 receptor blocker emedastine on acute seasonal allergic conjunctivitis and, if so, the time required for this effect to develop." | 9.10 | [Effects of emedastine eyedrops on acute seasonal allergic conjunctivitis in children]. ( Endre, L, 2003) |
| "Emedastine is superior to ketorolac in controlling itching and redness, the cardinal symptom and sign of allergic conjunctivitis." | 9.09 | Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. ( Abelson, M; Deschenes, J; Discepola, M, 1999) |
| "Emedastine is more efficacious than levocabastine in reducing chemosis, eyelid swelling and other efficacy variables associated with seasonal allergic conjunctivitis." | 9.09 | An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group. ( Abelson, MB; Deschenes, J; Discepola, M; Leonardi, A; Secchi, A, 2000) |
| "To assess the cost effectiveness of emedastine, a new antihistamine, versus levocabastine in the treatment of acute allergic conjunctivitis (AAC) in Belgium, France, Germany, The Netherlands, Norway, Portugal and Sweden." | 9.09 | Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries. ( Berdeaux, G; Fagnani, F; Lafuma, A; Nuijten, MJ; Pinto, CG, 2001) |
| "In a prospective, multicenter, randomized, double-masked, parallel group study, 222 patients with allergic conjunctivitis were randomized (221 received treatment) to either emedastine or levocabastine, instilled twice daily for 6 weeks." | 9.09 | Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. ( Abrantes, P; Apel, AJ; Brancato, R; Carmichael, TR; Cerqueti, PM; Ciprandi, G; Coroneo, MT; Coster, DJ; Easty, DL; Estivin-Ebrardt, C; Harrisberg, CJ; Kent-Smith, BT; Knorr, M; Leonardi, A; Martinez, M; Modorati, G; Nemeth-Wasmer, G; Partouche, P; Secchi, A; Verin, P, 2001) |
| "During the first experiment 20 children (suffering from acute seasonal allergic conjunctivitis) had received Emadine eye drop (containing emedastine difumarate, an H1 antihistamine agent)." | 7.74 | [The prompt effect of emedastine eye drop and the safety of its permanent use in children suffering from acute seasonal allergic conjunctivitis]. ( Endre, L, 2007) |
| "We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)." | 5.14 | Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. ( Akman, A; Akova, YA; Borazan, M; Erbek, SS; Karalezli, A; Kiyici, H, 2009) |
| " The aims of the present study were to establish whether there is a rapid effect of eyedrops containing the selective H1 receptor blocker emedastine on acute seasonal allergic conjunctivitis and, if so, the time required for this effect to develop." | 5.10 | [Effects of emedastine eyedrops on acute seasonal allergic conjunctivitis in children]. ( Endre, L, 2003) |
| "Emedastine is superior to ketorolac in controlling itching and redness, the cardinal symptom and sign of allergic conjunctivitis." | 5.09 | Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. ( Abelson, M; Deschenes, J; Discepola, M, 1999) |
| "Emedastine is more efficacious than levocabastine in reducing chemosis, eyelid swelling and other efficacy variables associated with seasonal allergic conjunctivitis." | 5.09 | An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group. ( Abelson, MB; Deschenes, J; Discepola, M; Leonardi, A; Secchi, A, 2000) |
| "To assess the cost effectiveness of emedastine, a new antihistamine, versus levocabastine in the treatment of acute allergic conjunctivitis (AAC) in Belgium, France, Germany, The Netherlands, Norway, Portugal and Sweden." | 5.09 | Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries. ( Berdeaux, G; Fagnani, F; Lafuma, A; Nuijten, MJ; Pinto, CG, 2001) |
| "In a prospective, multicenter, randomized, double-masked, parallel group study, 222 patients with allergic conjunctivitis were randomized (221 received treatment) to either emedastine or levocabastine, instilled twice daily for 6 weeks." | 5.09 | Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. ( Abrantes, P; Apel, AJ; Brancato, R; Carmichael, TR; Cerqueti, PM; Ciprandi, G; Coroneo, MT; Coster, DJ; Easty, DL; Estivin-Ebrardt, C; Harrisberg, CJ; Kent-Smith, BT; Knorr, M; Leonardi, A; Martinez, M; Modorati, G; Nemeth-Wasmer, G; Partouche, P; Secchi, A; Verin, P, 2001) |
| "During the first experiment 20 children (suffering from acute seasonal allergic conjunctivitis) had received Emadine eye drop (containing emedastine difumarate, an H1 antihistamine agent)." | 3.74 | [The prompt effect of emedastine eye drop and the safety of its permanent use in children suffering from acute seasonal allergic conjunctivitis]. ( Endre, L, 2007) |
| " Comparisons of relative potency 30 min post dosing between emedastine and other anti-histamines demonstrated that emedastine is equipotent to ketotifen, and 7, 7, 10, 10, 100, 357, 3333, and 5813 times more potent than brompheniramine, chlorpheniramine, clemastine, pyrilamine, levocabastine, pheniramine, diphenhydramine, and antazoline, respectively." | 1.29 | Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. ( Parnell, DW; Spellman, JM; Stephens, DJ; Yanni, JM, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 10 (76.92) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, RF | 1 |
| Wu, XX | 1 |
| Wang, X | 1 |
| Gao, J | 1 |
| Zhou, J | 1 |
| Zhao, Q | 1 |
| Borazan, M | 1 |
| Karalezli, A | 1 |
| Akova, YA | 1 |
| Akman, A | 1 |
| Kiyici, H | 1 |
| Erbek, SS | 1 |
| Endre, L | 2 |
| Haicl, P | 1 |
| Cerná, H | 1 |
| Sanchis-Merino, ME | 1 |
| Montero, JA | 1 |
| Ruiz-Moreno, JM | 1 |
| Rodriguez, AE | 1 |
| Pastor, S | 1 |
| Yanni, JM | 1 |
| Stephens, DJ | 1 |
| Parnell, DW | 1 |
| Spellman, JM | 1 |
| Discepola, M | 2 |
| Deschenes, J | 3 |
| Abelson, M | 1 |
| Secchi, A | 3 |
| Ciprandi, G | 2 |
| Leonardi, A | 3 |
| Abelson, MB | 2 |
| Netland, PA | 1 |
| Leahy, C | 1 |
| Krenzer, KL | 1 |
| Pinto, CG | 1 |
| Lafuma, A | 1 |
| Fagnani, F | 1 |
| Nuijten, MJ | 1 |
| Berdeaux, G | 1 |
| Verin, P | 1 |
| Easty, DL | 1 |
| Partouche, P | 1 |
| Nemeth-Wasmer, G | 1 |
| Brancato, R | 1 |
| Harrisberg, CJ | 1 |
| Estivin-Ebrardt, C | 1 |
| Coster, DJ | 1 |
| Apel, AJ | 1 |
| Coroneo, MT | 1 |
| Knorr, M | 1 |
| Carmichael, TR | 1 |
| Kent-Smith, BT | 1 |
| Abrantes, P | 1 |
| Cerqueti, PM | 1 |
| Modorati, G | 1 |
| Martinez, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Trial Comparing Olopatadine 0.1% Ophthalmic Solution With Hylo-Dual Ophthalmic Preparation in Children With Seasonal Allergic Conjunctivitis[NCT03186755] | Phase 4 | 42 participants (Anticipated) | Interventional | 2017-06-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 trials available for emedastine and Conjunctivitis, Allergic
4 other studies available for emedastine and Conjunctivitis, Allergic
| Article | Year |
|---|---|
[Topical H1 antihistaminics in the therapy of acute conjunctival allergic reactions].
Topics: Acute Disease; Adolescent; Adult; Anti-Allergic Agents; Benzimidazoles; Conjunctivitis, Allergic; Fe | 2004 |
[The prompt effect of emedastine eye drop and the safety of its permanent use in children suffering from acute seasonal allergic conjunctivitis].
Topics: Acute Disease; Adolescent; Adult; Anti-Allergic Agents; Benzimidazoles; Child; Conjunctivitis, Aller | 2007 |
Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis.
Topics: Animals; Anti-Allergic Agents; Benzimidazoles; Coloring Agents; Conjunctivitis, Allergic; Dibenzoxep | 2008 |
Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use.
Topics: Administration, Topical; Anaphylaxis; Animals; Benzimidazoles; Capillary Permeability; Conjunctiva; | 1994 |